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Patient and methods: Sixty patients aged 20–50 years ASA II or III scheduled for ERCP were
enrolled in this study. Patients were randomly allocated into two equal groups: dexmedetomi-
dine/propofol (DP) group and ketamine/propofol (KP) group. DP patients received a loading dose
of iv dexmedetomidine 1 lg/kg over 15 min then maintained by a 0.5 lg/kg/h. Group KP patients
received a loading dose of iv ketamine 1 mg/kg over15 min then maintained by 0.5 mg/kg/h. Induc-
tion of anesthesia was achieved with propofol 2 mg/kg, atracurium 0.5 mg/kg to facilitate endotra-
cheal intubation. Anesthesia was maintained by propofol infusion 5 mg/kg/h, intermittent iv
propofol boluses (0.5 mg/kg) were administered if needed. MAP and HR were recorded before
loading of study drugs (baseline) and recorded every 5 min after beginning of loading throughout
the procedure and just after intubation, then every 15 min for one hour post-operative. Total pro-
pofol consumption, recovery time, VAS and postoperative complications (PONV, cognitive dys-
function, and respiratory complications) were recorded.
Results: The intra-procedural HR and MAP showed high statistical signiﬁcant differences between
both groups throughout the procedure with lower values in DP group (p< 0.01 or <0.001). Dur-
ing the post-procedural period, the HR and MAP were signiﬁcantly lower in DP group. Propofol
consumption was comparable in both groups (268.0 ± 122.3 mg) in DP group versus
(304.7 ± 142.0 mg) in KP group. Postprocedural recovery time was signiﬁcantly shorter in DP
98 M.W. Abdalla et al.group (5.7 ± 1.7 min) compared with (22.2 ± 8.2 min) KP group (p< 0.01). VAS was comparable
in the two groups. PONV was 46.67% of KP group, while it was absent in DP group. Post-oper-
ative cognitive disorders showed a high statistical signiﬁcant difference between both groups
(p< 0.001) with no cases was reported in DP group. No respiratory complications in both groups.
Conclusion: Dexmedetomidine–propofol combination as TIVA during ERCP showed better intra-
and post-procedural hemodynamic stability, less PONV, less postoperative cognitive dysfunctions
and shorter recovery time when compared with ketamine–propofol combination.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) is
commonly used in the management of many pancreatobiliary
disorders. ERCP is the ideal method for extraction of common
bile duct stones; it reduced the need for the more invasive sur-
gical procedures associated with high morbidity particularly in
old age patients. ERCP with stent placement can be very effec-
tive for the palliation of obstructive jaundice In pancreatic
cancer patients [1,2].
In comparison with upper gastrointestinal endoscopic pro-
cedures, ERCP is a longer and more complex procedure, with
a substantially higher complication rate [3]. Sedation for gas-
trointestinal endoscopic procedures has gained much interest
in recent years. Sedation obviously ensures comfort for the
patients and endoscopists during the procedure, but sometimes
sedation in ERCP may be responsible for some postoperative
adverse events [4,5].
In fact, most complications in GI endoscopy are related to
sedation; including cardiopulmonary events such as hypox-
emia, hypoventilation, airway obstruction, apnea, arrythmia,
hypotension, and vasovagal episodes [6]. Raymonds and his
colleagues supported a continued preference for GA rather
than conscious sedation for ERCP especially when complex
and painful interventions are planned in prone position [7].
The introduction and availability of different pharmaceuti-
cal agents such as propofol, ketamine and dexmedetomidine
allow rapid induction of anesthesia while enabling rapid
recovery.
Dexmedetomidine is a stereoisomer of medetomidine. It is a
highly selective a2-agonist; eight times higher speciﬁcity for
receptors compared with clonidine. It seems to have better
hemodynamic parameters. It has a perioperative sedative,
analgesic and anxiolytic properties similar to benzodiazepines
but being a2 adrenoceptor agonist it has less side effects. Dex-
medetomidine provides analgesia with ceiling effect at doses
>0.5 lg/kg thus this effect is dose-dependent. Dexmedetomi-
dine is not a powerful anti-emetic and it has been shown to
cause much less respiratory depression than other sedatives.
However, co-administration of dexmedetomidine with other
anesthetic agents, sedatives, hypnotics, or opioids is likely to
cause additive effects, it attenuates but not completely abol-
ishes stress-induced sympatho-adrenal responses protecting
the patients from noxious sympathetic stimulation and hemo-
dynamic changes and that is one of the main anesthetic goals
[8–11].
Propofol is a non barbiturate sedative hypnotic; it has a
favorable pharmacokinetic proﬁle as the lipid solubility con-
fers a quick onset and short recovery time. It has also ananti-emetic, anticonvulsant, antipruritic and amnestic effects.
Although it is extremely effective and potent, propofol use is
limited by a relatively high incidence of dose-dependent hypo-
tension and respiratory depression [12].
Ketamine is a phencyclidine derivative. It provides excellent
amnesia and analgesia, preserves muscle tone with maintaining
airway reﬂexes and spontaneous respiration. Despite its obvi-
ous advantages over other agents, some practitioners are hes-
itant to use ketamine alone secondary to its ability to cause
frightening emergent reactions; additionally it has signiﬁcant
adverse effects including; sympathomimetic effects, vomiting
and excessive salivation even when administered in sedating
doses [13].
It is postulated that combining propofol–ketamine may
preserve sedative and analgesic efﬁcacy while minimizing their
respective adverse effects, this is partially due to the fact that
many of the adverse effects are dose-dependent and when the
two drugs used in combination the doses administered of each
can be reduced. Also, the CVS effects of each are opposing in
action, thus theoretically balancing each other when used
together. The theoretical advantages of this combination pro-
duce more stable hemodynamic and respiratory proﬁle that
were tested and found to be true in group of patients receiving
GA [14,15].
We hypothesized that the combination of propofol with
either dexmedetomidine or ketamine will improve the analgesic
and anesthetic effects of these drugs with lower doses and less
side effects. This will later help in providing adequate anesthe-
sia and analgesia in ERCP procedures requiring general
anesthesia.
This randomized comparative study was performed to com-
pare the effects of propofol/dexmedetomidine and propofol/
ketamine combinations in patients undergoing ERCP regard-
ing hemodynamic effects, intra-procedural propofol require-
ments as well as the recovery criteria and side effects.
2. Subjects and methods
The study was conducted after approval of the ethical and sci-
entiﬁc committee of the department of anesthesia in Kasr El
Aini hospital-Cairo University, and a written informed con-
sent was obtained from each participant in this study. Sixty
patients of both sexes aged 20–50 years scheduled for diagnos-
tic or therapeutic ERCP were enrolled in this study which was
conducted from March 2013 to March 2014. All patients were
of American Society of Anesthesiologist (ASA) class II or III.
Exclusion criteria included patients with allergy to study drugs,
patients with cardiovascular disease (hypertension, congestive
heart failure, and coronary artery disease), cerebrovascular
Propofol dexmedetomidine versus propofol ketamine for anesthesia 99insufﬁciency, increased intracranial tension, personality disor-
ders or suspected pregnancy in addition to those receiving anti-
psychotic or sedative medication.
Patients were randomly allocated into one of two parallel
treatment groups with allocation ratio of 1:1 and thirty
patients in each group. The allocation sequence was generated
using a randomized computer-generated sequence held by an
investigator not involved with the clinical management or data
collection.
 Dexmedetomidine/propofol (DP) group received iv dex-
medetomidine (1 lg/kg loading), followed by (0.5 lg/kg/h
infusion) and iv propofol infusion (5 mg/kg/h).
 Ketamine/propofol group (KP) group received iv ketamine
(1 mg/kg loading, followed by 0.5 mg/kg/h infusion) and
propofol infusion (5 mg/kg/h).
Pre-procedural evaluation included history taking, physical
examination and laboratory investigations (complete blood
picture, liver and kidney function tests, and coagulation pro-
ﬁle) and ECG. All patients were made familiar with the use
of 10 cm visual analogue scale score (VAS) identifying 0 as
no pain and 10 as the worst imaginable pain.
Before induction of anesthesia the study drugs (propofol,
dexmedetomidine, and ketamine) were prepared in identical
50 ml infusion syringes, the drugs were prepared as the
following:
 The propofol infusion syringe: A 50 ml syringe contained
10 mg/ml propofol (1% Fresenius Kabi Austria Gmbh
20 ml).
 Dexmedetomidine infusion syringe contained 100 lg dex-
medetomidine (precedex; united pharmaceutical group
company, USA) diluted by normal saline to have 50 ml
ﬁlled syringe (2 lg/ml).
 Ketamine infusion syringe contained 100 mg ketamine
(Ketamine; Sigma company) diluted with normal saline
to have 50 ml ﬁlled syringe (2 mg/ml).
Blinding of the study was ensured for the patients receiving
the treatment drugs, the investigators assessing the outcomes,
and the people analyzing the results/data. The study medica-
tions were prepared, and coded by an independent observer
who was not participating in any other part of the study and
the study drugs were administered by an anesthesiologist
who was not involved in the management of follow-up period
to maintain the double-blind nature of the study. But no blind-
ness to the propofol infusion syringe as sometimes there was a
need to decrease the infusion rate on occurrence of hypoten-
sion (a decrease >20% of baseline value).
2.1. Anesthetic procedure
On arrival to the operating room standard monitoring were
applied (ECG, automated non-invasive blood pressure moni-
toring and pulse oximetry) with recording of base line HR,
MAP, and oxygen saturation, then a 20 gauge iv cannula
was inserted on the dorsum of the hand and lactated ringer
solution was infused (6–8 ml/kg/h). Group DP patients
received a loading dose of iv dexmedetomidine 1 lg/kg over
15 min then maintained throughout the procedure by a rateof 0.5 lg/kg/h. Group KP patients received a loading dose of
iv ketamine 1 mg/kg over 15 min then maintained throughout
the procedure by a rate of 0.5 mg/kg/h.
After insertion of another 20 gauge iv cannula induction of
anesthesia was achieved with iv lidocaine 0.5 mg kg1 to
decrease pain induced by propofol injection, then propofol
2 mg/kg IV bolus, atracurium 0.5 mg/kg was used to facilitate
endotracheal intubation using a suitable sized cuffed endotra-
cheal tube. Controlled mechanical ventilation was instituted
with 100% oxygen. Capnography was applied and mechanical
ventilation was adjusted to maintain Et-CO2 at 30–35 mmHg.
Anesthesia was maintained by iv propofol infusion 5 mg/kg/h,
intermittent iv propofol boluses (0.5 mg/kg) were administered
to the patient guided by patient’s hemodynamic parameters
(20% increase in HR, and MAP above baseline values) and
atracurium top up doses 0.1 mg/kg was given every 20 min.
All operations were performed in the prone position. At the
end of the procedure all infusion drugs discontinued and rever-
sal of neuromuscular block was done by 0.05 mg/kg prostig-
mine and 0.01 mg/kg atropine followed by suctioning of
secretions and awake extubation after fulﬁlling the criteria of
extubation (patient is conscious, hemodynamic stability, spon-
taneous breathing and oxygen saturation >95%). Finally
patients will be transferred to recovery room.
The primary outcome was: assessment of heart rate and
mean arterial blood pressure changes during the procedure
and for one hour post-procedure. Secondary outcomes were
as follows: total propofol consumption by both groups
recorded at the end of the procedure, recovery time, level of
postoperative pain assessed by visual analogue scale, and inci-
dence of side effects (nausea and vomiting, postoperative cog-
nitive dysfunction, and any respiratory complications).
2.2. The recorded data
Mean arterial pressure (MAP) and heart rate (HR) were
recorded before administration of dexmedetomidine or keta-
mine loading (baseline), and continued every 5 min after begin-
ning of loading throughout the course of the procedure and
just after intubation. Any hemodynamic complications were
observed and recorded which included hypotension (a decrease
>20% of baseline value) or bradycardia (HR< 50 beat/min)
and they were treated according to the cause, in hypotension
infusion rate of propofol decreased, iv ﬂuids would be rapidly
infused and iv ephedrine 3–6 mg incremental doses repeated
after 5 min if no improvement. If bradycardia occurred the
endoscopist was asked to stop stimulation, and atropine
0.01 mg/kg was given. Hypertension or tachycardia (an
increase >20% of baseline values) also managed by giving
0.5 mg/kg iv propofol boluses to increase depth of anesthesia.
 MAP and HR were also recorded every 15 min for one hour
postoperatively.
 Propofol consumption was calculated and recorded at the
end of the procedure.
 Recovery time (time from extubation to spontaneous eye
opening) was recorded.
 After the procedure, patients were assessed every 15 min for
60 min regarding pain which was assessed by VAS, if
VAS > 3 pain was treated by 10–15 mg/kg paracetamol
IV infusion.
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giving iv 4 mg ondansetron.
 Postoperative cognitive dysfunction (hallucination, agita-
tion, or excitation) assessed and recorded every 15 min for
one hour postoperative.
 Any respiratory complications as labored breathing, respi-
ratory depression (RR< 10 bpm), or oxygen desaturation
(SpaO2 < 92%) were recorded. Oxygen mask was applied
to improve oxygen saturation.
 Procedural complications as bleeding, duodenal perforation
and cholangitis were recorded.
 Patients were discharged from recovery room when an
Aldrete score P9 was obtained (Table 1).
Statistical analysis: The sample size was based on data of
previous study [17] which indicated that a total sample size
of 60 patients (after exclusion of the drop out) randomly allo-
cated into two equal groups (30 patients in each group) is suf-
ﬁcient to ensure power 80% for detecting clinically meaningful
attenuation of heart rate and mean arterial blood pressure
changes by 10–20%, especially after induction of anesthesia
and intubation. Student’s t test for independent samples was
chosen to perform the calculation. a-error level was ﬁxed at
0.05 and the power was entered to be 80% and the groups
are assumed to be of equal size. Calculations were done using
PS Power and Sample Size Calculations Software, version
3.0.11 for MS Windows (William D. Dupont and Walton D.
Vanderbilt, USA).
Data were analyzed using IBM SPSS Advanced Statistics
version 20.0 (SPSS Inc., Chicago, IL). Numerical data were
expressed as mean and standard deviation. Qualitative data
were expressed as frequency and percentage. Chi-square testTable 2 Demographic and clinical characteristics and duration of
DP group (n= 30)
Age (years) 42.7 ± 8.7
Weight (kg) 60.7 ± 8.5
Sex (male/female) 20/10
ASA (II/III) 24/6
Duration of the procedure (min) 30.3 ± 8.2
Baseline MAP (mmHg) 101.9 ± 8.2
Baseline HR (beats/min.) 85.4 ± 10.0
Data are mean ± SD, or numbers.
P value >0.05 was considered statistically not signiﬁcant. P value <0.05
Group DP; dexmedetomidine/propofol group, Group KP; ketamine/prop
Table 1 Modiﬁed Aldrete recovery score [16].
Score Score
0 1
Activity (able to move
voluntary or on commands)
0 extremities 2 e
Respiration Apneic Dy
bre
Consciousness Unresponsive Re
SpO2 O2 saturation is <90% even with O2
supplementation
Ne
sat
Circulation BP ± 50 mmHg of preanesthetic
level
BP
lev(Fisher’s exact test) was used to examine the relation between
qualitative variables. For quantitative data, comparison
between two groups was done using independent sample t-test
or Mann-Whitney test. Comparison of repeated measures was
done using ANOVA test for repeated measures. A p-value
<0.05 was considered signiﬁcant.
3. Results
The current study was a comparative randomized study
between two groups; group-DP and group-KP with 30 patients
in each group (Fig. 1). Both groups had no statistical signiﬁ-
cant differences in demographic data (age, weight and sex),
ASA classiﬁcation and duration of the procedure, also, there
were no statistical signiﬁcant differences between both groups
as regard baseline of hemodynamic parameters (HR and
MAP) (Table 2).
The intra-procedural heart rate decreased signiﬁcantly in
DP group at 10 min till end of the procedure (p< 0.01), while
it increased signiﬁcantly in KP group (p< 0.001) from 5 min
till the end of the procedure with a high statistical signiﬁcant
differences between both groups throughout the procedure
(at 5 min, intubation time (I.T.), 10 min, 15 min, 20 min,
25 min, 30 min and 35 min); p-value was <0.01 at all mea-
sured times except at intubation time and 35 min P value
was <0.001; HR values were lower in dexmedetomidine–pro-
pofol group (Fig. 2).
The intra-procedural MAP decreased signiﬁcantly in DP
group (p< 0.01) from measuring at 5 min till end of the pro-
cedure, while it increased signiﬁcantly in KP group (p< 0.01)
from IT till the end of the procedure except at 15 and 20 min
(p> 0.05).the procedure in the two studied groups.
KP group (n= 30) p value
38.0 ± 10.7 0.067
61.8 ± 9.7 0.687
16/14 0.292
26/4 0.674
24.5 ± 7.5 0.134
100.8 ± 11.3 0.686
82.6 ± 11.4 0.316
was considered statistically signiﬁcant.
ofol group.
2
xtremities 4 extremities
spnea, shallow or limited
athing
Able to deep breathe &
cough freely
sponding to stimuli Fully awake
eds O2 to maintain O2
uration >90%
Able to maintain O2 saturation
>92% on room air
± 20–50 mmHg of preanesthetic
el
BP ± 20 mmHg of preanesthetic
level
Figure 1 Flow diagram displaying the progress of all participants through the study.
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Figure 2 Mean intra-procedural HR changes in the two studied
groups I.T.: intubation time, *P< 0.01, **P< 0.001 between
both groups.
Figure 2: Mean intra-procedural MAP in the two studied groups 
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Figure 3 Mean intra-procedural MAP changes in the two
studied groups I.T.: intubation time *P< 0.01, **P< 0.001, $:
P= 0.036 between both groups.
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between both groups; p-value was <0.001 at (5-min, 10-min,
15-min, 25-min, 30-min), while at IT and 35 min P value was
<0.001, and P-value at 20-min was 0.036 denoting statistical
signiﬁcant difference between both groups; MAP values were
lower in dexmedetomidine–propofol group (Fig. 3).
During the post-procedural period, the HR and MAP were
signiﬁcantly lower in DP group compared with KP groupstarting from 15 min to 60 min after the end of the procedure
with p-value was <0.01 at all measured times except at 60 min
for measuring MAP p= 0.035 (Figs. 4 and 5).
No atropine or ephedrine required for management of bra-
dycardia or hypotension.
The total dose of propofol was comparable in the two
groups (268.0 ± 122.3 mg) in DP group versus
(304.7 ± 142.0 mg) in KP group (p= 0.288) (Table 3).
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spontaneous eye opening) was signiﬁcantly shorter in DP
group (5.7 ± 1.7 min) compared with (22.2 ± 8.2 min) in KP
group (p= 0.01) (Table 3).0
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*
KP groupDP group
Figure 4 Comparison between dexmedetomidine/propofol (DP)
and ketamine/propofol (KP) groups as regard post-procedural
HR (beats/min). *P< 0.01 between both groups.
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Figure 5 Comparison between dexmedetomidine/propofol (DP)
and ketamine/propofol (KP) groups as regard post-procedural
MAP *P< 0.01, **P= 0.035 between both groups.
Table 3 Total dose of propofol, recovery time, post-procedural VA
DP gro
Total dose of propofol (mg) 268.0 ±
Recovery time (min.) 5.7 ± 1
VAS score
1–2 26 (86.6
3–5 4 (13.33
PONV 0 (0.0%
Hallucination or excitation (cognitive dysfunction) 0 (0.0%
Surgical complication 2 (6.67%
Data are means ± SD, or numbers and %.
P value >0.05 was considered statistically not signiﬁcant. P value <0.05
Group DP; dexmedetomidine/propofol group, Group KP; ketamine/propPost-procedural pain as assessed by VAS was comparable
in the two groups as 26 patients in DP group and all patients
in KP group (30 patients) had VAS 1–2 (p= 0.12) and only 4
patients in DP group had VAS of (3–5) (Table 3).
PONV occurred in about 46.67% of patients in KP group,
while it was absent in DP group (p< 0.001) it was managed by
giving 4 mg iv ondansetron. Post-operative cognitive disorders
(in the form of hallucination, agitation and excitation) showed
a high statistical signiﬁcant difference between both groups; p-
value was <0.001; no cases were reported in dexmedetomi-
dine–propofol group.
Modiﬁed Aldrete recovery score at 15 min was comparable
in both groups (9.16 ± 0.68 in DP group versus 9.02 ± 0.64 in
KP group with p> 0.05). There were no respiratory complica-
tions (labored breathing, apnea, or SPO2 < 92%) in both
groups.
Surgical complications were comparable in the two groups
(Table 3).
4. Discussion
The results of this study indicate that GA with Dexmedetom-
idine–propofol combination provided more hemodynamic sta-
bility, with shorter recovery time, less PONV, and no
postoperative cognitive dysfunction compared with keta-
mine–propofol combination in anesthesia for ERCP.
Patients planned for ERCP often have additional co-mor-
bidities that may make them candidates for GA. GA may be
required especially in high ASA, high BMI, gastrointestinal
bleeding, expected prolonged procedures, and previous failed
procedure [18,19]. Manukyan et al. [20] demonstrated that
GA shortened the duration of ERCP, increased the success
rate and prevented respiratory complications.
The current study demonstrated greater intra-procedural,
hemodynamic stability in dexmedetomidine–propofol group
in comparison with ketamine–propofol group. HR and MAP
values were lower in dexmedetomidine–propofol group
throughout the procedure, this may be related to the effect
of dexmedetomidine as highly selective a2-agonist so it has a
strong sympatholytic effect, while in ketamine and propofol
group mean arterial pressure was elevated above the base line,
this was due to increased diastolic pressure owing to increased
systemic vascular resistance.
Kang and his colleagues [17] supported the hemodynamic
stability of dexmedetomidine as they evaluated the effect ofS score and complications in the two studied groups.
up (n= 30) KP group (n= 30) p value
122.3 304.7 ± 142.0 0.288
.7 22.2 ± 8.2 <0.01
7%) 30 (100.0%) 0.120
%) 0 (.0%) >0.05
) 14 (46.67%) <0.001
) 10 (33.33%) <0.001
) 1 (3.33%) 0.554
was considered statistically signiﬁcant.
ofol group.
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remifentanil-based anesthesia on 20 patients that were ran-
domly divided into two groups one of them received dexmede-
tomidine as adjuvant to propofol remifentanil based anesthesia
and the other group received only propofol remifentanil, with
lower intra-procedural HR and MAP values at induction and
incision times in dexmedetomidine group. The study per-
formed by Tsai et al. [11] agreed the intraoperative hemody-
namic stability of dexmedetomidine as the current study,
they evaluated dexmedetomidine hemodynamic stability in
comparison with propofol in sedation for ﬁber-optic naso-tra-
cheal intubation in 40 patients with anticipated difﬁcult airway
undergoing elective surgery. Intra-procedural hemodynamic
stability was also supported by another study performed by
Sethi et al. [21] who studied dexmedetomidine versus midazo-
lam for conscious sedation in ERCP. They observed decreased
HR and comparatively stable MAP values in dexmedetomi-
dine group.
Contrary to these results another study by Muller et al. [22]
reported intra-procedural hemodynamic instability of dex-
medetomidine as they studied dexmedetomidine alone against
propofol–fentanyl for conscious sedation during ERCP. This
might be explained by the lighter level of sedation in dexmede-
tomidine group; they administered dexmedetomidine in load-
ing dose 1 lg/kg infused over 10 min then maintained by
0.2 lg/kg/h that requiring additional sedatives.
Bajwa et al. [23] compared two drugs combinations in Total
Intravenous Anesthesia: propofol–ketamine (group-I) versus
propofol–fentanyl (group-II), there was an increase in intra-
operative HR and MAP values in group-I while they decreased
in group-II after induction and intubation with a statistical sig-
niﬁcant difference between both groups; these results were in
accordance with results of ketamine propofol group in the cur-
rent study.
On the other hand Mahajan et al. [24] compared ketamine
and fentanyl with propofol and fentanyl in TIVA and found
that there was slight increase in intra-procedural pulse rate
after induction in both groups that was statistically non signif-
icant. The difference between Mahajan et al. study and the cur-
rent study might be due to the different lower basal pulse rate
and MAP in their study, also the premedication with 0.03 mg/
kg midazolam IV, and the different type of patients as Maha-
jan’s et al. patients were ASA I, II while the current study
patients were ASA-II and III with controlled co-morbidities
like DM and hypertension.
Post-procedural HR and MAP changes in the current
study showed high statistical signiﬁcant difference between
both groups throughout PACU-period; with HR and MAP
values lower in dexmedetomidine–propofol group, this was
supported by a study performed by Sethi et al. [21] using
dexmedetomidine versus midazolam for conscious sedation
in ERCP with stable post-procedural MAP and lower HR
values in dexmedetomidine group compared with midazolam
group.
Demiraran et al. [25] compared dexmedetomidine and
midazolam for sedation of upper endoscopy. There was no sta-
tistical signiﬁcance between both groups as regards postopera-
tive hemodynamic parameters HR and MAP (p-value >0.05).
Bajwa et al. [23] studied two drugs combinations: propofol–
ketamine and propofol–fentanyl in TIVA. They noticed that
post-procedural HR in both groups increased at 1 and 5 min
after extubation, this was in agreement with the current study.On the other hand post-procedural hemodynamic derange-
ment did not occur in patients received ketamine–propofol
combination in a study performed by Aydogan et al. [26]
who studied ketamine–propofol combination versus propofol
alone in upper GI-endoscopy in adults.
Total propofol consumption by the end of the procedure in
the current study was lower in dexmedetomidine–propofol
group but with no statistical signiﬁcant difference (p= 0.288).
Kang et al. [17] studied dexmedetomidine versus placebo in
remifentanil-based anesthesia. They reported signiﬁcant differ-
ence in total propofol consumption by the end of their proce-
dure (63.9 ± 16.2 lg/kg/h) in dexmedetomidine, versus
(96.4 ± 10.0 lg/kg/h) in placebo with P-value <0.001. This
lower values of propofol consumption in their study than val-
ues of the current study could be explained by the differences
in dexmedetomidine maintenance dose and the addition of
remifentanil infusion to anesthetic technique might play a syn-
ergistic role in Kang et al. study.
On the other hand propofol consumption in a study per-
formed by Saric et al. [27] was (352.65 ± 109.44 mg) in keta-
mine–propofol group versus (380 ± 135.4 mg) in propofol
alone for deep sedation during ERCP in elderly, P-value was
0.0268. This was more than the propofol consumption
reported in the current study; this might be due to the lower
dose of ketamine as they administered ketamine as a single
bolus (25 mg) after losing ciliary reﬂex by propofol bolus.
Total propofol consumption by patients received ketamine–
propofol combination was reported by a study performed by
Aydogan et al. [26]. They found that ketamine–propofol group
consumed (72 ± 12 mg) versus (92 ± 10 mg) consumed by
propofol group; the consumed amount of propofol by keta-
mine–propofol group in Aydogan et al. study was less than
that reported by the current study, this might due to the dura-
tion of the endoscopy that appeared to be shorter than ERCP
(5.5 ± 0.096 min) in Aydogan et al. study versus
(24.50 ± 7.51 min) in the current ERCP study.
Post-procedural recovery time of the current study (time
from extubation to spontaneous eye opening) was signiﬁcantly
shorter in dexmedetomidine–propofol group than ketamine–
propofol group. Sethi et al. [21] supported this ﬁnding as they
reported shorter recovery time for dexmedetomidine group in
patients undergoing ERCP under conscious sedation; and
90% of patients received dexmedetomidine achieved Alderte
score 9–10 within 5 min. These results were contrary to Demir-
aran et al. study [25] that demonstrated prolonged recovery
time of dexmedetomidine (42 ± 12.5 min) which was more
than the current study, this may be due to difference of the
procedure in both studies. The duration of their simple proce-
dure (upper endoscopy) was (8.9 ± 1.3 min) in dexmedetomi-
dine group compared with (30.3 ± 8.2 min) in the current
study as ERCP is more complex, prolonged and painful proce-
dure than the upper endoscopy.
Aydogan et al. [26] reported shorter recovery time in
their study (7.26 ± 6.8 min) in patients received ketamine–
propofol versus (10.30 ± 3.6 min) in patients received fenta-
nyl–propofol undergoing upper gastro-intestinal endoscopy.
The difference between recovery time reported in Aydogan
et al.; and that recorded in KP group by the current study
might be due to the different type of their procedure; that
lapse for (5.516 ± 0.096 min), more simpler and less com-
plex, in addition to the lower ketamine dose (0.25 mg/kg
bolus).
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shorter (11.19 ± 19 min) than that detected by the current
study (22.2 ± 8.2 min) as regard ketamine–propofol group;
this might be due to the lower ketamine dose that was admin-
istered in conjunction with propofol (1:4) for induction of deep
sedation in their study while the current study used GA as an
anesthetic plan that required more anesthetic doses.
Post-procedural nausea and vomiting in the current study
showed a high statistical signiﬁcant difference between both
groups; P-value <0.001. The incidence was higher in keta-
mine–propofol group (14 cases i.e. 46.67%), while no reported
cases in dexmedetomidine–propofol group.
Demiraran et al. [25] supported the current study as they
studied midazolam versus dexmedetomidine for sedation of
patients undergoing upper endoscopy. There were no reported
cases of PONV in dexmedetomidine group.
PONV was 2% in patients received ketamine–propofol
combinations by Aydogan et al. [26] versus no case reported
in the other group received propofol alone in patients undergo-
ing upper gastro-intestinal endoscopy; this was much lower
than the incidence reported in the current study, this might
be due to different type of the procedure and the lower keta-
mine dose (0.25 mg/kg as one bolus dose) used in their study.
The incidence of PONV detected by Hasanein and El-Sayed
[28] was 3% in patients received ketamine propofol for seda-
tion of obese patients undergoing ERCP without statistical sig-
niﬁcant difference with the other group that received fentanyl–
propofol combination. The reported PONV by Hasanein and
El-Sayed; was less than that detected by the current study as
they used lower ketamine dose and the intention was for seda-
tion not GA.
Post-procedural pain in the current study was assessed by
VAS showed no statistical differences between both groups,
with all patients of ketamine propofol group were VAS (1–
2), compared with 26 patients from the dexmedetomidine–pro-
pofol group, this high analgesic effect of ketamine is related to
being NMDA receptor antagonist, also ketamine has agonist
activity at mu-opioid receptors, while the anti nociceptive
action of dexmedetomidine is due to being selective a2-agonist.
Dexmedetomidine provides analgesia with a ceiling effect at
doses >0.5 lg/kg. Previous study detected that opioid require-
ments in the intraoperative period and in the post-anesthetic
care unit (PACU) are reduced by dexmedetomidine [11].
Demiraran et al. [25] results supported the current study
ﬁnding as regard incidence of pain. As they assessed the inci-
dence of post-procedural abdominal discomfort in patients
undergoing upper endoscopy received dexmedetomidine versus
midazolam, there was a lower pain incidence in patient receiv-
ing dexmedetomidine than those receiving midazolam but this
difference did not reach statistical signiﬁcance (p= 0.21).
The current study reported post-operative cognitive disor-
ders in the form of hallucination, agitation and excitation, it
showed a high statistical signiﬁcant difference between both
groups; with higher incidence in ketamine–propofol group
(33.33%) and no cases in DP group. Agitation and irritability
reported by Hasanein and El-Sayed study [28] was 2% in
patients receiving ketamine–propofol combination versus no
reported cases in the other comparative group that received
propofol–fentanyl. This incidence was lower than that
reported in ketamine–propofol group of the current study, this
might be due to their lower ketamine dose used for sedation.Mahajan et al. [24] also reported lower incidence of post-
operative cognitive dysfunction (8/50) than the current study;
they studied ketamine–propofol versus fentanyl–propofol for
TIVA, despite the higher ketamine dose used in their study
(1 mg/kg ketamine + 2 mg/kg propofol) for induction fol-
lowed by (2 mg/kg/h ketamine + 4 mg/kg/h propofol) for
maintenance. This lower incidence might be due to different
type of patients as patients in the current study had liver
impairment, and elevated liver enzymes with hyperbilirubine-
mia that may alter the pharmacokinetics and pharmacody-
namic effects of ketamine.
Respiratory adverse events did not occur in both groups of
the current study.
Demiraran et al. [25] studied the dexmedetomidine versus
midazolam for sedation in upper endoscopy. In midazolam
group, apnea was developed in one patient and two patients
suffered from desaturation (SPO2 < 90%) while no deteriora-
tion in respiratory parameters (respiratory rate, desaturation)
were observed in dexmedetomidine group; this result was in
accordance with that reported in the current study.
On the other hand Bajwa et al. study [23] and a study
performed by Aydogan et al. for upper GI endoscopy [26]
did not report any cases of respiratory impairment in keta-
mine–propofol group; this was compatible with the current
study.
The current study has some potential limitations as the
small sample size, so further studies with larger number of
patients are needed to test the efﬁcacy and safety of the study
drugs when used as TIVA technique to maintain better intra-
and post-procedural hemodynamic stability with lower post-
operative complications. Another limitation was inability to
assess intraoperative depth of anesthesia and incidence of
intraoperative awareness as the BIS monitor was unavailable,
however the intensity of noxious stimuli that the patients
received during surgery might be relatively homogeneous
because of the uniform surgery. Therefore, we believe that
there may have been only a small difference in anesthetic depth
between the groups during the study period. Also the duration
of assessment of postoperative hemodynamic changes, and
VAS as well as complications were limited to one hour in
PACU, so further studies with extended period of postopera-
tive assessments are required as those patients may have differ-
ent drug metabolism due to their liver impairment. Finally the
cost effectiveness was not evaluated in the current study.
Dexmedetomidine–propofol combination as TIVA tech-
nique requires further studies to be adequately evaluated with
recommendation to include larger number and different types
of patients; as elderly and critically ill patients.
5. Conclusion
Dexmedetomidine–propofol combination as TIVA during
ERCP showed better intra- and post-procedural hemodynamic
stability, less PONV, less postoperative cognitive dysfunctions
and shorter recovery time when compared with ketamine–pro-
pofol combination.
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